Clinical trials: Acute Coronary Syndromes (ACS)
- Condition Acute Coronary Syndromes (ACS)
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acute Coronary Syndrome
RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
This NIS is a multi-centre, observational, descriptive, cross-sectional study including all consecutive patients with Acute Coronary Syndrome (ACS) and a single-arm, prospective, longitudinal cohort study which will include…
- Trial name
- STREAM (NCT02288260)
- Where
- 15 sites in Russia
- Volunteers
- 5,470 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India.
- Trial name
- TREASURE (NCT02408224)
- Where
- 31 sites in India
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Fondaparinux EU-RMP (Adherence)
Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by Health Canada in March 2007 and by the EMEA in September 2007.
- Trial name
- NCT01406301
- Testing
- fondaparinux
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk.
- Trial name
- CHI SQUARE (NCT01201837)
- Testing
- CER-001
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 507 people
- Sponsor
- Cerenis Therapeutics, SA